In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Discover which stocks are splitting, the ratio, and split ex-date with the latest information from EDGAR® Online LLC. Data provided by and © 2024 EDGAR® Online LLC ...

Spotify Technology S.A. 2.24% $100.74B ...

2-Year U.S. Treasury Note Continuous Contract $102.914 0.027 0.03% 5-Year U.S. Treasury Note Continuous Contract $106.602 0.102 0.10% 10-Year U.S. Treasury Note Continuous Contract $109.203 0.172 ...

Bonus Dec 03, 2024 Dec 03, 2024 Oct 17, 2024 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Mar 06, 2019 Mar 07, 2019 Jan 18, 2019 Bonus Ratio: 1 share(s) for every 3 shares held Bonus Jun 13, ...

Bonus Jul 13, 2017 Jul 14, 2017 May 29, 2017 Bonus Ratio: 1 share(s) for every 2 shares held Bonus Jul 11, 2013 Jul 13, 2013 May 22, 2013 Bonus Ratio: 1 share(s) for every 2 shares held Bonus Oct 01, ...

Vodafone Idea Ltd., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 64,182.34 Crore) operating in Telecommunications sector. Vodafone Idea Ltd. key Products/Revenue ...